New markers for minimal residual disease detection in acute lymphoblastic leukemia

This publication has 52 references indexed in Scilit:

• Preemptive alloimmune intervention in high-risk pediatric acute lymphoblastic leukemia patients guided by minimal residual disease level before stem cell transplantation
  Leukemia, 2010
• Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia
  Blood, 2010
• MLL-Rearranged B Lymphoblastic Leukemias Selectively Express the Immunoregulatory Carbohydrate-Binding Protein Galectin-1
  Clinical Cancer Research, 2010
• Role of Minimal Residual Disease Monitoring in Adult and Pediatric Acute Lymphoblastic Leukemia
  Hematology/Oncology Clinics of North America, 2009
• Treating Childhood Acute Lymphoblastic Leukemia without Cranial Irradiation
  New England Journal of Medicine, 2009
• Overexpression of CD123 correlates with the hyperdiploid genotype in acute lymphoblastic leukemia
  Haematologica, 2009
• Reinduction Platform for Children With First Marrow Relapse of Acute Lymphoblastic Leukemia: A Children's Oncology Group Study
  Journal of Clinical Oncology, 2008
• Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study
  Blood, 2008
• Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01
  Blood, 2007
• Expression of Functional B7-H2 and B7.2 Costimulatory Molecules and Their Prognostic Implications inDe novoAcute Myeloid Leukemia
  Clinical Cancer Research, 2005